189 related articles for article (PubMed ID: 24778992)
1. Clonal non-malignant hematological disorders: unraveling molecular pathogenic mechanisms to develop novel targeted therapeutics.
Risitano AM; Selleri C
Transl Med UniSa; 2014 Jan; 8():1-3. PubMed ID: 24778992
[TBL] [Abstract][Full Text] [Related]
2. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes.
Risitano AM; Maciejewski JP; Selleri C; Rotoli B
Curr Stem Cell Res Ther; 2007 Jan; 2(1):39-52. PubMed ID: 18220891
[TBL] [Abstract][Full Text] [Related]
3. Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria.
Meletis J; Terpos E
Med Sci Monit; 2003 Jul; 9(7):RA161-72. PubMed ID: 12883466
[TBL] [Abstract][Full Text] [Related]
4. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity and malignancy in hematology--more than an association.
Stern M; Buser AS; Lohri A; Tichelli A; Nissen-Druey C
Crit Rev Oncol Hematol; 2007 Aug; 63(2):100-10. PubMed ID: 17391977
[TBL] [Abstract][Full Text] [Related]
6. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
Ye B; Sheng Y; Zhang M; Hu Y; Huang H
Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
[TBL] [Abstract][Full Text] [Related]
7. Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005).
Gluzman D; Imamura N; Sklyarenko L; Nadgornaya V; Zavelevich M; Machilo V
Exp Oncol; 2006 Mar; 28(1):60-3. PubMed ID: 16614710
[TBL] [Abstract][Full Text] [Related]
8. Hematological Neoplasms with Eosinophilia.
Morales-Camacho RM; Caballero-Velázquez T; Borrero JJ; Bernal R; Prats-Martín C
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254826
[TBL] [Abstract][Full Text] [Related]
9. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.
Cada M; Segbefia CI; Klaassen R; Fernandez CV; Yanofsky RA; Wu J; Pastore Y; Silva M; Lipton JH; Brossard J; Michon B; Abish S; Steele M; Sinha R; Belletrutti M; Breakey V; Jardine L; Goodyear L; Sung L; Shago M; Beyene J; Sharma P; Zlateska B; Dror Y
Haematologica; 2015 May; 100(5):633-42. PubMed ID: 25682607
[TBL] [Abstract][Full Text] [Related]
10. Clonal hematopoiesis in hematological disorders: Three different scenarios.
Swierczek S; Prchal JT
Exp Hematol; 2020 Mar; 83():57-65. PubMed ID: 32007480
[TBL] [Abstract][Full Text] [Related]
11. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
12. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Sun L; Babushok DV
Blood; 2020 Jul; 136(1):36-49. PubMed ID: 32430502
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?
Semenzato G; Ghobrial IM; Ghia P
Lancet Haematol; 2023 Jul; 10(7):e549-e556. PubMed ID: 37407144
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes and overlap syndromes.
Chang YH
Blood Res; 2021 Apr; 56(S1):S51-S64. PubMed ID: 33935036
[TBL] [Abstract][Full Text] [Related]
15. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.
Risitano AM
Transl Med UniSa; 2014 Jan; 8():43-52. PubMed ID: 24778997
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.
Hazan-Halevy I; Landesman-Milo D; Rosenblum D; Mizrahy S; Ng BD; Peer D
J Control Release; 2016 Dec; 244(Pt B):149-156. PubMed ID: 27491881
[TBL] [Abstract][Full Text] [Related]
17. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
[TBL] [Abstract][Full Text] [Related]
18. Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?
Zambello R; Teramo A; Gattazzo C; Semenzato G
Transl Med UniSa; 2014 Jan; 8():4-11. PubMed ID: 24778993
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal B-cell lymphocytosis (MBL, CD4+/CD8 weak T-cell large granular lymphocytic leukemia (T-LGL leukemia) and monoclonal gammopathy of unknown significance (MGUS): molecular and flow cytometry characterization of three concomitant hematological disorders.
Matos DM; de Oliveira AC; Tomé Mde N; Scrideli CA
Med Oncol; 2012 Dec; 29(5):3557-60. PubMed ID: 22688448
[TBL] [Abstract][Full Text] [Related]
20. Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell data.
Kim SY; Park Y; Kim H; Kim J; Kwon GC; Koo SH
Clin Chim Acta; 2018 May; 480():56-64. PubMed ID: 29378171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
